TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03835910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Incentives and Gamification to Promote Exercise
Description: The intervention will provide social incentives and gamification to promote physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Incentives and Gamification to Promote Exercise
Description: The intervention will provide social incentives and gamification to promote physical activity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection given in A-B order
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticosteroid Injection given in A-B order
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Social Incentive applied
Description: No social incentive will be applied

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Social Incentive applied
Description: No social incentive will be applied

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection given in B-A order
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticosteroid Injection given in B-A order
Description: The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
Study: NCT01626495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
Study: NCT04120948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterlase Express Laser System
Description: 10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tongue scraper
Description: mechanical scraping of the dorso-posterior surface of the tongue
Study: NCT04148820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin, Atorvastatin, Perindopril
Description: Cardiovascular drugs will be administered all together every day at the same time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin, Atorvastatin, Perindopril
Description: Cardiovascular drugs will be administered all together every day at the same time
Study: NCT02498613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Correlative studies
Study: NCT04389255

Intervention type: OTHER
Intervention: Star Excursion Balance Test
Description: The Star Excursion Balance Test (SEBT) is a dynamic test that requires strength, flexibility, and proprioception. It is a measure of dynamic balance that provides a significant challenge to athletes and physically active individuals. The test can be used to assess physical performance, but can also be used to screen deficits in dynamic postural control due to musculoskeletal injuries (e.g. chronic ankle instability), to identify athletes at greater risk for lower extremity injury, as well as during the rehabilitation of orthopeadic injuries in healthy active adults.\[

Intervention type: DEVICE
Intervention: Balance Master device
Description: The Balance Master (Neurocom International, Inc Clackamas,) device is a computerized posturography device. The device consists of a fixed support surface consisting of a force table and individuals, a variety of ground elements and a computer screen that will provide visual feedback and conduct test protocols. Posturography tests a person's ability to integrate visual, vestibular and somatosensory inputs and suppress inappropriate sensory information. Thus, it can quantitatively score the person's balance and examine balance problems in detail with the tests it contains. There are various protocols that evaluate balance differently in Balance Master (BMc). Limits of Stability Test (LOS) and Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) were used in the BMc.
Study: NCT04069546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: RIC is a physical strategy performed by an electric device with cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times.
Study: NCT03381391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: The current intervention included personalized feedback regarding their alcohol consumption, alcohol-related consequences, gender-specific normative drinking comparisons, personal risk factors (e.g., dependence symptoms, family history of alcoholism), and alcohol expectancies. The intervention also included didactic material related to alcohol (e.g., effects at different BAC levels, tolerance) and drinking moderation strategies. The feedback was presented graphically in a feedback report with the individual's information.
Study: NCT00555347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Dosage 150-250 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00884611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictive Low Glucose Suspend Algorithm ON
Description: The algorithm uses a Kalman filter-based model to predict whether the sensor glucose level will fall below 80 mg/dL within a given time period and suspends the insulin pump if this event is predicted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictive Low Glucose Suspend Algorithm OFF
Study: NCT04315220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corestability training
Description: Level -1: Mat exercises~Abdominal muscle contraction,bridging,cat stretch,single limb circle and superman.:~Level- 2: Swiss Ball Exercises Abdominal contraction,bridging and squats.
Study: NCT02528058

Intervention type: PROCEDURE
Intervention: Vitrectomy with internal limiting membrane peeling
Study: NCT03610451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floatation-REST plus usual care
Description: Individuals will receive Floatation-REST plus usual care. Floating creates an environment with minimal visual, auditory, tactile, proprioceptive, and thermal input to the brain. The float rooms are lightproof and soundproof. A high concentration Epsom salt water solution allows individuals to effortlessly float on their back while remaining completely still, reducing both proprioceptive and tactile input to the brain. The temperature of the water is calibrated to the temperature of the skin (\~94° F) and the temperature of the air is calibrated to the temperature of the water, making it difficult to discern the boundary between air and water, thus reducing thermal input to the brain while minimizing the need for thermoregulation of the skin.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Individuals will receive usual care on the inpatient unit of the Laureate Eating Disorders Program.
Study: NCT03298373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
Study: NCT01897441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT03298373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11β-methyl-nortestosterone-dodecylcarbonate
Description: 11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
Study: NCT02193477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TEAS
Description: Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
Study: NCT01897441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT03528096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnomat B
Description: Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
Study: NCT01897441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT03528096

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sound
Description: Sound of the moving bed was recorded and played back during the baseline night.
Study: NCT04030338

Intervention type: DRUG
Intervention: 18F-DCFPyL-iPSMA
Description: Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.

Intervention type: DRUG
Intervention: 68Ga-HBED-iPSMA
Description: Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT scan
Description: The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed
Study: NCT01547507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirWay Medix Closed Suction System
Description: AirWay Medix Closed Suction System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirWay Medix Closed Suction System
Description: AirWay Medix Closed Suction System
Study: NCT01897441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Patients with ER-positive, HER2-negative disease may receive neoadjuvant endocrine therapy (NET) with an aromatase inhibitor: (either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily) for 4-6 months prior to surgery (or longer if clinically indicated). Anastrozole for 6 months is the preferred regimen for NET.
Study: NCT02959710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204 mixed in water
Description: 40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204 mixed in water
Description: 40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204 mixed in water
Description: 40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
Study: NCT02927782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bed Rest
Description: 48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
Study: NCT02955797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 milliliter (mL), Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine
Description: 0.5 mL, Intramuscular
Study: NCT02770170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064 dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064 dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064 dose 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01443273

Intervention type: OTHER
Intervention: Medical Records study
Description: No interventions will be done related to the study besides summary of the Medical Files.
Study: NCT02028312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Restasis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Study: NCT04357340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Physiotherapy Techniques
Description: Participants will receive pulmonary physiotherapy techniques in six session during three days (twice daily). Four distinguished interventions will be provided for the patients: 1) Chest expansion exercises (for prevention and treatment of potential atelectasis); 2) Techniques to Mobilize or loosen the pulmonary secretions (Active cycle breathing, Coughing techniques, Vibration and Postural drainage); 3) Hold breathing exercise (3 sets, 10 repetition) and; 4) Walking training (based on patient's tolerance until 6 minute).
Study: NCT02660931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AKI Risk Notification
Description: When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
Study: NCT05076396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM14
Description: PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety. Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
Study: NCT03203070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizol iv
Description: Postoperative analgesia iv with Metamizol 2g/8h will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol iv
Description: Postoperative analgesia iv with Metamizol 2g/8h will be administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Intraoperative laparoscopic-guided TAP block will be performed with 30ml Bupivacaine 0.5%
Study: NCT02759874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: specialized breathalyzer w face recognition technology
Study: NCT03624244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Maintenance of AI versus interruption of AI

Intervention type: DRUG
Group type: OTHER
Intervention: Aromatase Inhibitors
Description: Maintenance of AI versus interruption of AI
Study: NCT01898208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilmArray testing
Description: FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
Study: NCT02959710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202 mixed in water
Description: 60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202 mixed in water
Description: 60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202 mixed in water
Description: 60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202 mixed in Ensure®
Description: 60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202 mixed in Ensure®
Description: 60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)
Study: NCT03756961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: The control group receives Oxycodone as the routine pain management drug post-operative.
Study: NCT01898208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial Stewardship
Description: Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial culture
Description: This test identifies the pathogen responsible for an infection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial culture
Description: This test identifies the pathogen responsible for an infection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial culture
Description: This test identifies the pathogen responsible for an infection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Susceptibility testing
Description: Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Susceptibility testing
Description: Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Susceptibility testing
Description: Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
Study: NCT04160962

Intervention type: PROCEDURE
Intervention: lappg
Description: Laparoscopic gastrectomy for pylorus preservation

Intervention type: PROCEDURE
Intervention: lappg
Description: Laparoscopic gastrectomy for pylorus preservation